In breast cancers, the risk of brain metastasis varies differently among hormone positive (~14%), Human epidermal growth factor receptor-2 (HER2) positive (~34%), and triple negative (~46%) receptor subtypes [5,6,7,8]. Here, ERBB2 is linked to breast carcinoma.